ANTITHROMBOTIC THERAPY IN CANCER PATIENTS

Abstract

The article describes the main anticoagulant drugs used in cancer patients, taking into consideration pathogenetic aspects of hypercoagulation status in cancer patients: oral anticoagulants, heparin drugs, selective inhibitors of Xa factor. The basic advantages of low molecular weight heparin compared with unfractioned heparin. The comparison of low-molecular weight heparin drugs, their generics and biosimilar drugs is surveyed. Reviewed recommendations for the prevention of thrombotic complications in cancer patients. Overviewed the possible complications of heparin therapy and methods of prevention.

Keywords

• low-molecular weight heparin
• oral anticoagulants
• heparin-indused thrombocytopenia
• thrombosis prophylaxis
• anti- xa drugs